NRG2025 Summer NRG Web Hero.png

NRG2025 Summer Meeting

Thank you for joining us in Washington, DC and virtually for online sessions 
during the NRG2025 Summer Meeting. 

Visit our #NRG2025 Summer Meeting page
for session presentations as they become available. 

Search for clinical trials.

Search Publications Search Protocols

A Focus On Science

NRG Oncology and its partners have more than 150 years experience in conducting practice-defining, multi-institutional phase II and III trials sponsored primarily by the National Cancer Institute (NCI), as well as a history of undertaking the kind of phase I trials and translational biological studies that will be imperative for future clinical cancer research.

 

>
NCI Community Oncology Research Programs NCI National Clinical Trials Program

Uniquely positioned

Internationally recognized investigators populate the leadership and membership of all seven cancer disease site committees encompassed by NRG Oncology.

  • Brain tumors
  • Breast cancer
  • Gastrointestinal cancer
  • Genitourinary cancer
  • Gynecologic cancer
  • Head and Neck cancer
  • Lung cancer
Learn More For Patients
NRG is a platform to find better treatment for cancer of tomorrow.

Ending Cancer

Ending cancer as we know it means commitment to research. Commitment for funding, commitment to participate, and commitment from researchers. Working together makes a difference. Cynthia Licavoli, RN

Ending Cancer

Our Mission

Improve the lives of patients with cancer by conducting practice-changing multi-institutional clinical and translational research

Dr. Robert S. Mannel

Our exceptional network brings individuals together who are passionate about changing the future of cancer care through impactful clinical trials.

Membership Resources

NRG Oncology's membership roster is comprised of over 1,000 member sites including institutions on five continents. Our investigators represent all of the oncologic medical specialties and disciplines.

Learn More

Latest News

Card image cap
NRG Oncology Trial Analysis Shows Improvement in Survival Outcomes for Glioblastoma Patients Receiving Proton Therapy, Trial Moves to Phase III

Previously, results from the photon cohort of NRG-BN001, a signal seeking Phase II randomized trial, indicated that photon radiation dose intensification (75 Gy) did not demonstrate improvement in overall survival (OS) for patients with newly diagnosed glioblastoma (GBM). The recent analysis of the proton cohort revealed improved survival for patients receiving proton therapy at 75 Gy. Because this data met the pre-defined survival improvement threshold, they could be used to design and conduct a definitive phase III randomized trial. These results were recently reported at the American Society for Radiation Oncology Annual Meeting in San Francisco, California.

Read More
Card image cap
Patient-Reported Outcome Analysis of NRG Oncology Trial in Limited-Stage Small Cell Lung Cancer Suggests Quality of Life Benefit with Twice - (vs Once -) Daily Radiation

Read More
Card image cap
NRG Oncology Trial Results Show Favorable Bowel Health Related Quality of Life Outcomes for Localized Intermediate Risk Prostate Cancer Treated with Stereotactic Body Radiation Therapy

Read More
See All Posts

Stay current with science. Sign up for our newsletter.

Support NRG Oncology.
Help Our Cause.

We are one of the leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.